A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. The optimal antigen response of chimeric antigen receptors harboring the CD3 transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors. A V HH-based anti-MUC1 chimeric antigen receptor for specific retargeting of human primary T cells to MUC1-positive cancer cells. Rajabzadeh, A., Rahbarizadeh, F., Ahmadvand, D., Kabir Salmani, M. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. The T-body approach: potential for cancer immunotherapy. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
0 kommentar(er)
